Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 10, 2009

Millipore Steps Into European Market with Purchase of BioAnaLab

  • Millipore has acquired BioAnaLab to expand its biopharmaceutical services into Europe. Its facility in Oxford, U.K., specializes in the analysis of biologics and vaccines. It will complement Millipore’s existing site for large molecule bioanalytical services in St. Charles, MO.

    “As an increasing number of biologics enter the pipeline, companies are leveraging Millipore’s ligand-binding assay expertise to help them evaluate the efficacy of these drugs and achieve regulatory compliance,” says Jonathan DiVincenzo, President of Millipore’s Bioscience Division.

    “Our acquisition of BioAnaLab will allow us to build on our reputation as a trusted outsource partner in North America by establishing a presence in the fast-growing European biotech market. BioAnaLab will add cGMP support testing capabilities to our portfolio, a solid customer base, and a team of highly talented services professionals with expertise in emerging scientific disciplines.”

    BioAnaLab was spun out of the University of Oxford in 2002. Services offered include assay transfer/development, validation and sample analysis, pharmacokinetics/toxicokinetics, immunogenicity, biological potency, and vaccine services. Millipore will bring substantial expertise in biomarker analytical services to strengthen BioAnaLab’s current offering in that area.

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »